Zymeworks closes public offering of 5,824,729 common shares

On January 27, 2020, Zymeworks closed its underwritten public offering of 5,824,729 common shares, including the exercise in full of the underwriters’ over-allotment option to purchase 900,000 additional shares, and, in lieu of common shares, to a certain investor, pre-funded warrants to purchase up to 1,075,271 common shares. The common shares were offered at a price to the public of US$46.50 per common share and the pre-funded warrants were offered at a price of US$46.4999 per pre-funded warrant, for aggregate gross proceeds to Zymeworks of approximately US$320.8 million.

Zymeworks announced that it intends to use the proceeds from this offering to accelerate and expand the global development of anti-cancer agents and for general corporate purposes.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics.

McCarthy Tetrault acted as Canadian counsel JP Morgan Chase, the underwriters, with a team led by David Frost that included Bosa Kosoric, Erin O’Callaghan, and Thomas Fung.